Organisation paid for research Program year 2021 Source: CMS Open Payments

UCLA Medcl Ctr

Neither a doctor nor a teaching hospital

Research payments

$157,799

58 payments

Through program year 2021, UCLA Medcl Ctr is reported as receiving $157,799 in research payments, across 58 payments.

By program year

2 rows

Year	Kind	Amount	Payments
2021	Research	$151,128	38
2019	Research	$6,672	20

Breakdown

Who paid Research payments · program years 2019–2021

Boehringer Ingelheim Pharma GmbH & Co.KG $116,080 27 payments
Boehringer Ingelheim International GmbH $35,033 18 payments
Boehringer Ingelheim Pharmaceuticals, Inc. $3,918 1 payment
Boehringer Ingelheim France S.A.S. $1,332 9 payments
Boehringer Ingelheim RCV GmbH & Co KG $1,244 1 payment
Boehringer Ingelheim Limited $191 2 payments

Studies the money was for Research payments · program years 2019–2021

Phase I Abemaciclib + BI 836845 $81,644 3 payments
Empa-Kidney $65,132 16 payments
Phase II III in UC patients $3,918 1 payment
BI 685509 Dose finding/PoCC in DKD $1,474 1 payment
Phase II PoCP $1,332 9 payments
Phase II/III in UC patients $1,244 1 payment
Extension $1,240 4 payments
Nintedanib - PF-ILD $1,106 14 payments
Nintedanib in PF-ILD (extension) $590 7 payments
Systemic Sclerosis (ILD) pivotal study $119 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.